STK25-induced inhibition of aerobic glycolysis via GOLPH3-mTOR pathway suppresses cell proliferation in colorectal cancer
- 113 Downloads
Serine/threonine protein kinase 25 (STK25) is critical in regulating whole-body glucose and insulin homeostasis and the accumulation of ectopic lipids. The Warburg effect, also known as aerobic glycolysis, is an essential metabolic characteristic of cancer cells. However, the effects of STK25 on aerobic glycolysis of cancer cells remain unexplored. The aim of this study is to investigate the role of STK25 in colorectal cancer (CRC) and to elucidate the underlying mechanisms.
The influences of STK25 on the cell proliferation were evaluated by MTT and colony formation assays. The roles of STK25 in aerobic glycolysis were determined by glucose uptake and lactate production assays. The interaction between STK25 and GOLPH3 was detected by co-immunoprecipitation, GST pull-down, and His-tag pull-down assays. Western blot was used to measure the expression of glycolytic genes, and the status of kinases in mTOR pathway. Moreover, a xenograft mouse model was used to investigate the effects of STK25 in vivo. The prognostic significance of STK25 was analyzed using public CRC datasets by a log-rank test.
STK25 suppressed proliferation, glycolysis and glycolytic gene expression in CRC cells. STK25 interacted with GOLPH3 and mediated glycolysis through GOLPH3-regulated mTOR signaling. Consistent with these observations, silencing of STK25 promoted tumor growth and glycolytic gene expression in an in vivo xenograft mouse model. Moreover, high levels of STK25 correlated with favorable prognosis in patients with CRC.
Our results demonstrated that STK25 negatively regulates the proliferation and glycolysis via GOLPH3-dependent mTOR signaling. Accordingly, STK25 could be a potential therapeutic target for the treatment of CRC.
KeywordsSTK25 GOLPH3 Colorectal cancer (CRC) Glycolysis mTOR
American Type Culture Collection
Fetal bovine serum
- GCK III
Germinal center kinase III
Golgi matrix protein 130
Mammalian target of rapamycin
mTOR complex 1
mTOR complex 2
quantitative real-time PCR
Serine/threonine protein kinase 25
Colorectal cancer (CRC) is one of the most common malignancies and the second leading cause of cancer-related death in the world [1, 2]. Although notable progress has been made in the diagnosis and treatment of CRC, there are still challenges in determining the molecular mechanisms of tumor invasion, metastasis, and recurrence . Thus, there is an urgent need for a greater understanding of the genetic and epigenetic alterations that lead to tumorigenesis in CRC, to improve the efficacy of disease treatments, including surgical techniques, adjuvant radiation, chemotherapy therapy, and follow-up strategies.
The Warburg effect, or aerobic glycolysis, is a critical feature of cancer cells, which have the tendency to employ glycolysis, even in the presence of sufficient oxygen [4, 5]. To generate energy, cancer cells convert their glucose into lactate, supplying a primary route for the carbon source that is required for macromolecular biosynthesis. This process enables cancer cells to meet the increasing energetic demands needed by rapid tumor growth [4, 5]. Thus, determining underlying molecular mechanism of aerobic glycolysis activation in cancer may shed light on the initiation and progression of cancer to identify potential drug targets.
Serine/threonine protein kinase 25 (STK25), also known as YSK1 and SOK1, is a member of the germinal center kinase III (GCK III) subfamily of the sterile 20 (STE20) kinase superfamily [6, 7]. STK25 plays pivotal roles in several biological processes, including the regulation of cell polarization and migration, promotion of cell death under extreme stresses, and modulation of Golgi morphology [8, 9, 10, 11, 12, 13]. Importantly, previous studies have demonstrated that STK25 regulates whole-body glucose and insulin homeostasis, and the accumulation of ectopic lipids [7, 14, 15, 16, 17, 18, 19]. Transgenic mice that overexpress STK25 experience lower glucose utilization and insulin sensitivity and elevated lipid deposition in the liver and pancreas, compared to wild-type littermates, when fed a high-fat diet . Conversely, in STK25 knockout mice, Amrutkar et al. reported improved systemic glucose tolerance and insulin sensitivity, as well as reduced ectopic lipid storage in the liver and skeletal muscle . Moreover, in type 2 diabetic patients, STK25 mRNA levels are significantly elevated in skeletal muscle, compared with healthy volunteers with normal glucose tolerance . Thus, STK25 is a potential drug target for metabolic disease. However, the role of STK25 in aerobic glycolysis in cancer cells remains less well characterized.
The PI3K/AKT/mTOR pathway contributes to various cellular processes, including protein synthesis, cell growth, survival, autophagy, and metabolism [20, 21, 22, 23, 24]. This signaling cascade is upregulated in several human cancers and plays a critical role in modulating aerobic glycolytic metabolism [25, 26, 27, 28]. mTOR is composed of two multiprotein complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) . mTORC1 stimulates HIF1α and glycolytic enzymes, which induce glycolysis . mTORC2 enhances the acetylation of FoxO1 and FoxO3, and the release of c-Myc from a suppressive miR-34c-dependent network, which results in the upregulation of glycolytic metabolism in cancer . Due to the function of mTOR in glycolysis during tumorigenesis, whether STK25 is involved in mTOR signaling is needed to be elucidated.
In this study, we investigated the role of STK25 in glycolysis in CRC cells and the underlying molecular mechanisms. Our study demonstrates that STK25 inhibits aerobic glycolysis and malignant phenotypes in CRC. The interaction between STK25 and GOLPH3 contributes to the regulation of glycolysis through the mTOR signaling pathway. Moreover, high STK25 expression correlated with a favorable prognosis in patients with CRC. Taken together, these findings suggest that STK25 could serve as a potential target in the treatment of cancers that correlate with dysregulated glycolysis that is induced by activation of mTOR signaling.
Cell lines and cell culture
The RKO, LoVo, HCT116, and SW480 human CRC cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA). Cells were maintained in RPMI-1640 or DMEM medium (HyClone) that was supplemented with 10% FBS (PAA), penicillin 100 units/mL, and streptomycin 100 μg/mL in a humidified atmosphere with 5% CO2 at 37 °C.
Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated from CRC cells and tissues using Trizol (Invitrogen). Synthesis of first-strand cDNA was performed with a reverse transcription kit (Promega, Madison, WI, USA). For the qRT-PCR, we used the SYBR Green PCR Master Mix system (Toyobo Co. Ltd., Osaka, Japan) with the primers that are listed in Additional file 1: Table S1. Expression was quantified as the level of the indicated genes relative to an internal control, GAPDH, by ΔCt method .
Western blot analysis
Western blot was carried out as described . The primary antibodies were used at the following dilutions: STK25 (1:1000, Cat #25821–1-AP, Proteintech), GOLPH3 (1:1000, Cat #19112–1-AP, Proteintech), PDHK1 (1:1000, Cat #3820, Cell Signaling Technology), HK2 (1:1000, Cat #2867, Cell Signaling Technology), LDHA (1:1000, Cat #2012, Cell Signaling Technology), AKT (1:1000, Cat #9272, Cell Signaling Technology), p-AKT (1:1000, Cat #9271, Cell Signaling Technology), mTOR Substrates Antibody Sampler Kit (1:1000, Cat #9862, Cell Signaling Technology), p70S6K (1:1000, Cat #2708, Cell Signaling Technology), p-p70S6K (1:200, Cat #9234, Cell Signaling Technology), and GOLPH3 (1:1000, Cat #19112–1-AP, Proteintech). The protein levels were normalized to β-actin (1,3000, Cat #A1978, Sigma-Aldrich). The densities of the proteins were quantified with ImageJ software.
Plasmids and siRNA transfections
The cDNA of full-length STK25 was cloned into pCMV-3Tag-1A. The ON-target plus SMARTpool STK25 small inhibitor RNA (siRNA) (human: #L-004873-00-0005) was purchased from Dharmacon. GOLPH3 siRNAs and negative control siRNA were synthesized as described (Shanghai Gene Pharma, China) . CRC cells were transiently transfected with plasmids or siRNAs using Lipofectamine™ 2000 (Invitrogen) according to the manufacturer’s instructions.
Cell proliferation and colony formation assay
Cells were seeded into a 96-well plate at 0.5 × 104 cells/well with complete medium at 37 °C. To determine the numbers of live cells, MTT reagent was added to each well at 0, 24, 48, 72, and 96 h, respectively. The spectrometric absorbance at 570 nm was detected with a microplate reader (Bio-Rad, USA). To determine clonogenic ability, the cells were seeded into a 6-well plate at 250 cells/well and incubated for 14 days. Cell colonies were stained with 0.01% crystal violet and counted. These experiments were performed in triplicate.
Lactate production and glucose uptake assays
Cells that were transfected with plasmids or siRNAs were cultured in complete medium for 48 h. The culture medium and original medium were collected to determine lactate and glucose levels using the EnzyChrom™ L-Lactate Assay Kit (BioAssay Systems) and the Amplex Red Glucose/Glucose Oxidase Assay Kit (Invitrogen), respectively.
Co-immunoprecipitation (co-IP) assay
For Co-IP of Flag-STK25 and Myc-GOLPH3, 1 μg of Flag antibody (Cat#F1804, Sigma-Aldrich, USA) or c-Myc antibody (Cat#631206, Clontech, USA) was incubated with 10 μL of rProtein A sepharose beads (GE Healthcare) for 2 h at 4 °C. Then, 500 μg of total protein in cell lysis buffer was added to the mixture and incubated for 4 h at 4 °C. The immunoprecipitates were washed three times with lysis buffer, after which the immunoprecipitates and inputs were analyzed by western blot using Flag antibody (1:1000) and c-Myc antibody (1:500).
GST pull-down and his-tag pull-down assays
Human STK25 was inserted into the pET-28a(+) vector. The pGEX-4 T-1-GOLPH3 plasmid has been described . His-STK25, GST-GOLPH3, and GST were expressed and purified in accordance with the manufacturer’s instructions (Amersham). Then, 10 μg of His-STK25 was mixed with 10 μg of GST-GOLPH3 or GST and incubated with glutathione sepharose 4B beads (GE Healthcare) and Ni-NTA agarose (QIAGEN), respectively, for the GST pull-down and His-tag pull-down assays. The pellets were washed three times and boiled in SDS loading buffer. The bound proteins were loaded onto a 12% SDS-polyacrylamide gel and examined by western blot with anti-GST and anti-His tag (Beijing Zhongshan Golden Bridge Biotechnology Co Ltd., China).
The animal studies were approved by the Animal Ethics Committee of Peking University Cancer Hospital & Institute and were carried out in accordance with institutional guidelines. LoVo-shSTK25 and LoVo-shControl cells (~ 5 × 106) were injected subcutaneously in 4-week-old female BALB/c-nude mice. Tumor growth was measured using calipers twice per week. Tumor volume was calculated by the following formula: 0.5 × L × W2 . At 4 weeks after tumor inoculation, the tumor weight was measured.
MicroPET/CT imaging of mice was performed as described [33, 34]. In brief, xenograft-bearing mice were administered 100–200 μCi [18F] FDG via tail vein injection. The mice were scanned in a Super Argus PET/CT scanner (Sedecal, Spain). Images were displayed by an MMWKS Super Argus.
Analysis of gene expression datasets
The normalized mRNA expression data and CRC sample clinical information were downloaded from GEO (http://www.ncbi.nlm.nih.gov/geo/). Differences in STK25 expression between CRC tissues and adjacent noncancerous tissues were analyzed using paired-sample t-tests. The patients in each dataset were classified as STK25-high and STK25-low according to their mRNA levels of STK25. Survival curves were determined using the Kaplan-Meier method. The comparisons between groups were investigated by log-rank test. Overall survival was calculated as the time from the primary surgery to death or date of last follow-up. Recurrence-free survival was defined as the time from the primary surgery to recurrence or death from any cause. All statistical analyses were performed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA). A two-sided P value of < 0.05 was considered to be statistically significant .
STK25 inhibits CRC cell growth
The effects of STK25 on CRC cell growth was measured by MTT and colony formation assays. The results suggested that overexpression of STK25 significantly decreases cell proliferation and colony formation in LoVo and RKO cells (Fig. 1e, g). However, knockdown of STK25 significantly promoted malignant phenotypes (Fig. 1f, h). These findings indicate that STK25 inhibits CRC cell growth.
STK25 suppresses aerobic glycolysis and the expression of glycolytic genes in CRC cells
To determine whether STK25 regulates aerobic glycolysis in CRC, glucose uptake and lactate production assays were performed. The analysis of extracellular metabolites showed that STK25 overexpression significantly decreased glucose consumption and lactate production, leading to a lower lactate: glucose ratio in CRC cells (Fig. 2b-d, left two panels). However, STK25 silencing markedly elevated glucose consumption, lactate production, and lactate: glucose ratios (Fig. 2b-d, right two panels). These findings suggest that STK25 suppresses aerobic glycolysis in CRC cells.
STK25 interacts with GOLPH3 and regulates its expression
STK25 localizes to the Golgi apparatus and is involved in the pathway that is required for cell migration and polarization [11, 12]. GOLPH3 is a peripheral membrane protein in the Golgi stack that mediates Golgi trafficking . Thus, it has been postulated that there might be associations between STK25 and GOLPH3.
Next, to evaluate whether STK25 regulates GOLPH3 expression in CRC cells, we overexpressed or knocked down STK25 in CRC cells and measured GOLPH3 levels. STK25 overexpression significantly reduced the expression of GLOPH3 at the mRNA and protein levels (Fig. 4e), whereas STK25 knockdown upregulated it (Fig. 4f).
Moreover, to determine whether there is a feedback loop between STK25 and GOLPH3, we assessed whether GOLPH3 could regulate the expression of STK25. The results showed that overexpression or knockdown of GOLPH3 had little effects on STK25 protein levels in CRC cells (Additional file 2: Figure S1).
STK25 mediates glycolysis via GOLPH3
To further investigate whether STK25 regulates aerobic glycolysis through GOLPH3 in CRC cells, we knocked down STK25 and GOLPH3 using siRNAs in LoVo cells. As expected, STK25 depletion promoted glucose consumption and lactate production, which were impeded by knockdown of GOLPH3 in LoVo (Fig. 5d, e) and RKO cells (Additional file 3: Figure S2). These findings suggest that STK25 regulates aerobic glycolysis in part by modulating the expression of GOLPH3.
STK25 modulates mTOR signaling through GOLPH3
Next, to determine the role of GOLPH3 in STK25-regulated mTOR signaling, we knocked down GOLPH3 and STK25 with siRNAs and measured the phosphorylation of AKT and S6K. GOLPH3 depletion suppressed the induction of AKT and S6K phosphorylation on STK25 silencing (Fig. 6c). These data raise the possibility that STK25 modulates mTOR signaling through GOLPH3.
STK25 regulates glycolysis through mTOR signaling
mTOR signaling contributes to the activation of cellular glycolysis [25, 26, 27], and our data suggest that STK25 regulates glycolysis in part through mTOR signaling. To test this hypothesis, we abolished the activity of mTOR with rapamycin and knockdown of STK25 and measured glucose consumption and lactate production in CRC cells. As expected, rapamycin impaired glucose consumption and lactate production in a dose-dependent manner (Additional file 4: Figure S3). More importantly, rapamycin completely abrogated the promoting effects of STK25 depletion on glucose consumption and lactate production (Fig. 6d, e). Taken together, these results indicate that STK25 regulates glycolytic metabolism in CRC cells through the mTOR pathway.
STK25 depletion promotes tumor growth and glycolytic gene expression in a xenograft mouse model
Additionally, the tumor tissues were analyzed to evaluate the differences in STK25 and glycolytic gene expression. By western blot, lower STK25 expression in STK25 shRNA-expressing tumors was associated with upregulation of GLUT1, HK2, LDHA, and PDHK1 compared with shControl-expressing tumors (Fig. 7e), which is consistent with the in vitro data. To confirm the influence of STK25 on glycolysis, microPET/CT imaging of mice was performed to compare the uptake of 18F-FDG by the tumors. 18F-FDG accumulation was significantly enhanced by STK25 depletion (Fig. 7f). These findings indicate that the silencing of STK25 promotes tumor growth and increases glycolysis in tumors.
High levels of STK25 suggest a better prognosis in patients with CRC
According to STK25 mRNA levels, patients in each dataset were classified into STK25 high- and low-expressing groups, based on the median gene expression value. To determine the prognostic value of STK25 in survival, Kaplan-Meier survival plots were drawn and log-rank test were performed. In the GSE33113 CRC dataset, patients with STK25-high tumors had significantly longer recurrence-free survival than those with low levels (P = 0.046, Fig. 8c). Similarly, in the GSE28722 dataset, patients with elevated STK25 levels showed a borderline significant association with improved overall survival, compared with those with reduced levels (P = 0.075, Fig. 8d). These findings suggest that high levels of STK25 predict an improved prognosis for patients with CRC.
In the current study, we identified STK25 as a suppressor of proliferation and glycolysis in CRC cells. STK25 mediated glycolysis through its interaction with GOLPH3, modulating mTOR signaling. Moreover, high levels of STK25 indicated a favorable prognosis in patients with CRC. These findings suggest that STK25 inhibits aerobic glycolysis, thus impairing the proliferation of CRC cells.
As a critical signaling molecule, STK25 is involved in Golgi organization, cell migration and polarity, cell death and apoptosis, cardiovascular development, and energy metabolism [7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 36]. STK25 localizes to the Golgi apparatus and is activated via interaction with Golgi matrix protein 130 (GM130), contributing to cell migration and polarity [10, 11]. STK25 translocates from the Golgi apparatus to the nucleus in response to chemical anoxia and results in the regulation of cell death . STK25 interacts with CCM3 (PDCD10), promotes apoptosis under oxidative stress, and controls endothelial cell junctions by regulating Rho via directly activating moesin, which contributed to cardiovascular development and human vascular disease . Furthermore, STK25 is a new regulator of whole-body energy homeostasis, which is critical in glucose utilization, insulin sensitivity, and ectopic lipid deposition, through the control of triacylglycerol (TAG) synthesis in vivo and in vitro [7, 14, 15, 16, 17, 18, 19]. Consequently, STK25 is a potential target for the treatment of type 2 diabetes .
According to the role of STK25 in regulating glucose utilization in human hepatocytes, we investigated whether STK25 has effects on glycolysis in CRC cells. Consistent with a previous study in human hepatocytes, which reported suppression of glucose uptake by overexpression of STK25 , our results suggest that STK25 attenuates aerobic glycolysis and downregulates glycolytic genes in CRC cells.
Accumulating evidence has demonstrated that mTOR pathway is crucial in aerobic glycolysis and tumorigenesis [20, 21, 22, 23, 24, 25, 26, 27, 28]. mTOR consists of two multi-protein complexes: mTORC1 and mTORC2 . mTORC1 is a critical activator of glycolysis, upregulating PKM2, Glut3, and other glycolytic enzymes under normoxic conditions [27, 28]. mTORC2 has been reported to control glycolytic metabolism via FoxO acetylation and c-Myc upregulation in glioblastoma .
In the present study, we identified STK25 as a regulator and interactor of GOLPH3. GOLPH3 is identified as an oncoprotein, which is frequently amplified in several tumors [35, 37], and shuttles between Golgi apparatus and mitochondria to promote mitochondrial biogenesis and function in breast cancer cells, enhancing anabolic tumor growth [35, 38, 39]. Since GOLPH3 activates mTOR signaling through the phosphorylation of specific substrates of mTORC1 and mTORC2, increasing the sensitivity of tumor cells to rapamycin in vivo . Thus, we investigated the effects of STK25 in regulating mTOR signaling. Our results suggested that STK25 modulates the mTOR cascade in a GOLPH3-dependent manner. Moreover, mTOR signaling is required for STK25-regulated glycolysis. Collectively, these results raise the possibility that STK25 promotes glycolysis by activating the GOLPH3-mTOR pathway.
The functions of STK25 in cancer development and progression are debated. A previous study suggested that STK25 is highly expressed in prostate cancer, compared with benign prostatic hyperplasia, contributing to prostate tumorigenesis . However, in neuroblastoma patients, Costa et al. demonstrated that high STK25 levels in tumors are associated with a better prognosis and that STK25 acts as an effector of the death signaling pathway that is initiated by TrkA and CCM2 . Consistent with the study by Coata et al., our analysis of public datasets indicates that high levels of STK25 correlate with a favorable clinical outcome in patients with CRC.
There are several limitations of this study. Although we demonstrated a correlation between STK25 and GOLPH3, which regulates mTOR signaling-dependent glycolysis, the effects of STK25 and GOLPH3 on rapamycin-mediated glycolysis should be investigated. Furthermore, to validate the clinical value of STK25 in patients with CRC, replication cohorts that include clinicopathological variables are required.
In conclusion, our findings demonstrate that STK25 inhibits cell proliferation and glycolysis via GOLPH3-dependent mTOR signaling. Additionally, CRC patients with STK25-high tumors have improved survival. These data implicate STK25 as a potential target for the Warburg effect in cancer therapy.
This study was supported by the grants from National Natural Science Foundation of China (81672439, 81450028, 81272766, 81470129, 81402346), Beijing Natural Science Foundation (7162039, 7132054, 7172042), Beijing Health System High-level Health Technical Personnel Training Program (2015–3-074), Capital’s Funds for Health Improvement and Research (CFH 2018–2-2153), the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (XM201309, ZYLX201701).
Availability of data and materials
All data generated or analyzed during this study are included in this published article (and its additional files).
XS and BJ conceived and designed the study. FW and PG performed the experiments. FW, PG, and WW analyzed the data. ZW, JY, and JD contributed reagents, materials, and analysis tools. PG, FW, and BJ wrote the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This study was approved and supervised by the Research Ethics Committee of Peking University Cancer Hospital and Institute, Beijing, China (No. 2016KT37).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 37.Rizzo R, Parashuraman S, D'Angelo G, Luini A. GOLPH3 and oncogenesis: What is the molecular link? Tissue Cell 2017;49(2 Pt A):170–174.Google Scholar
- 38.Salem AF, Whitaker-Menezes D, Lin Z, Martinez-Outschoorn UE, Tanowitz HB, Al-Zoubi MS, et al. Two-compartment tumor metabolism: autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells. Cell Cycle. 2012;11(13):2545–56.CrossRefPubMedPubMedCentralGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.